Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Progesterone Resistance 1Polycystic Ovary Syndrome 1Obesity 1Endometrial Neoplasms 1Endometrial Hyperplasia 1

Interventions

enzalutamide 94Magnetic Resonance Spectroscopy 86Specimen Handling 66Prednisone 66Androgen Antagonists 60Abiraterone Acetate 58apalutamide 56Radiosurgery 53darolutamide 48Radiotherapy 47Leuprolide 47abiraterone 46Docetaxel 43Pluvicto 32Radiation 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Biopsy 30Surveys and Questionnaires 29relugolix 28pembrolizumab 26gallium 68 PSMA-11 26Standard of Care 26Triptorelin Pamoate 25Goserelin 25bicalutamide 23Gonadotropin-Releasing Hormone 23Brachytherapy 21Carboplatin 20cabazitaxel 19X-Rays 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- × 1 year × Clear all
NCT06613100 2026-05-14

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

Amgen

Phase 1 Recruiting
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

OHSU Knight Cancer Institute

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡